Manuscripts

General

1. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology.2008 Aug;115(8):1366-71, 1371.e1 (Published).
(Manuscript) |  View Publication   
 
2. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU; Diabetic Retinopathy Clinical Research Network. Diabetic macular edema: what is focal and what is diffuse?. Am J Ophthalmol.2008 Nov;146(5):649-55.e1-6. (Published).
(Manuscript) |  View Publication   
 
3. Glassman AR, Beck RW, Browning DJ, Danis RP, Kollman C; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of optical coherence tomography in diabetic macular edema, with and without reading center manual grading from a clinical trials perspective. Invest Ophthalmol Vis Sci.2009 Feb;50(2):560-6 (Published).
(Manuscript) |  View Publication   
 
4. Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Effects of dilation on Electronic-ETDRS Visual Acuity in diabetic patients. Invest Ophthalmol Vis Sci.2009 Apr;50(4):1580-4. (Published).
(Manuscript) |  View Publication   
 
5. Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; Diabetic Retinopathy Clinical Research Network. The Risk of Endophthalmitis Following Intravitreal Injection in the DRCR.net Laser-Ranibizumab-Triamcinolone Clinical Trials. Arch Ophthalmol. 2009 Dec;127(12):1581-3 (Published).
(Manuscript) |  View Publication   
 
6. Ferris FL, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of ocular coherence tomography data for use in clinical research. Ophthalmology 2010 Aug;117:1512–1516 (Published).
(Manuscript) |  View Publication   
 
7. Sun JK, Aiello LP, Cavallerano JD, Stockman M, Miller KM, Qin H, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Visual acuity testing using autorefraction or pinhole as compared with manual DRCR protocol refraction in individuals with diabetes. Ophthalmology.2011 Mar;118:537–542 (Published).
(Manuscript) |  View Publication   
 
8. Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, for the Diabetic Retinopathy Clinical Research Network. Comparison of Film and Digital Fundus Photographs in Eyes of Individuals with Diabetes Mellitus. IOVS 2011 Aug;52:6168-73 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
9. Bhavsar AR, Stockdale CR, Ferris FL III, Brucker AJ, Bressler NM, Glassman AR, for the Diabetic Retinopathy Clinical Research. Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical Antibiotics. Arch Ophthalmol. 2012 Jun;130(6):809-810 (Published).
(Manuscript) |  View Publication   
 
10. Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA. 2014 Jun 11;311(22):2269-70 (Published).
(Manuscript) |  View Publication   
 
11. Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Elimination of topical antibiotics for intavitreous injections and the importance of using povidone-iodine: Update from the Diabetic Retinopathy Clinical Research Network. Jama Ophthal.2016 August. doi:10.1001/jamaophthalmol.2016.2741 (Published).
(Manuscript) |  View Publication   
 
12. Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, Jhaveri CD, Salehi-Had H, Velez G, Sun JK; DRCR Retina Network. Anti-Vascular Endothelial Growth Factor Therapy and Risk of Traction Retinal Detachment in Eyes with Proliferative Diabetic Retinopathy: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. Retina.2020 Jun;40(6):1021-1028. doi: 10.1097/IAE.0000000000002633. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
13. Lujan BJ, Calhoun CT, Glassman AR, Googe JM, Jampol LM, Melia M, Schlossman DK, Sun JK, for the DRCR Retina Network. Optical coherence tomography angiography quality across three multicenter clinical studies of diabetic retinopathy. Trans Vis Sci Tech. 2021;10(3):2,https://doi.org/10.1167/tvst.10.3.2 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
14. Baker CW, Josic K, Maguire MG, Jampol LM, Martin DF, Rofagha S, Sun JK; DRCR Retina Network. Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment. Ophthalmology. 2023 May;130(5):533-541. doi: 10.1016/j.ophtha.2022.12.008. Epub 2022 Dec 12. PMID: 36521571; PMCID: PMC10291514 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
15. Sun JK, Beaulieu WT, Melia M, Ferris FL 3rd, Maturi RK, Nielsen JS, Solomon SD, Jampol LM; DRCR Retina Network. Defining "strong versus "weak" response to antivascular endothelial growth factor treatment for center-involved diabetic macular edema. Retina. 2023 Apr 1;43(4):616-623. doi: 10.1097/IAE.0000000000003730. PMID: 36728692 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol A - Laser Photocoagulation for Diabetic Macular Edema

1. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JI, Miskala PH. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology.2007 Mar;114(3):525-36 (Published).
(Manuscript) |  View Publication   
 
2. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Lauer AK, Recchia FM, Solomon SD. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol.2007 Apr;125(4):469-80 (Published).
(Manuscript) |  View Publication   
 
3. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci.2008 May;49(5):1745-52 (Published).
(Manuscript) |  View Publication   
 
4. Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; Diabetic Retinopathy Clinical Research Network. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina.2009 Mar;29(3):300-5 (Published).
(Manuscript) |  View Publication   
 
5. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H; Diabetic Retinopathy Clinical Research Network. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. Retina 2009 May;29(5):613-7 (Published).
(Manuscript) |  View Publication   
 
6. Danis RP, Scott IU, Qin H, Altaweel MM, Bressler NM, Bressler SB, Browning DJ, Kollman C; Diabetic Retinopathy Clinical Research Network. Association of fluorescein angiographic features with visual acuity and with OCT and stereoscopic color fundus photographic features of DME in a randomized clinical trial. Retina.2010 Dec;30(10):1627-37 (Published).
(Manuscript) |  View Publication   
 

Protocol AA - UWF Risk of DR Worsening Over Time

1. Aiello LP, Odia I, Glassman AR, Melia M, Jampol LM, Bressler NM, Kiss S, Silva PS, Wykoff CC, Sun JK, for the Diabetic Retinopathy Clinical Research Network. Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmol. 2019 Jan 1;137(1):65-73. doi: 10.1001/jamaophthalmol.2018.4982 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Silva PS, Liu D, Glassman AR, Aiello LP, Grover S, Kingsley RM, Melia M, Sun JK, DRCR Retina Network. Assessment of fluorescein angiography nonperfusion in eyes with diabetic retinopathy using ultrawide field retinal imaging. Retina. 2022 Jul 1;42(7):1302-1310. doi: 10.1097/IAE.0000000000003479. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
3. Marcus DM, Silva PS, Liu D, Aiello LP, Antoszyk A, Elman M, Friedman S, Glassman AR, Googe JM, Jampol LM, Martin DF, Melia M, Preston CM, Wykoff CC, Sun JK; DRCR Retina Network. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. Published online August 18, 2022. doi:10.1001/jamaophthalmol.2022.3131 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
4. Silva PS, Marcus DM, Liu D, Aiello LP, Antoszyk A, Elman M, Friedman S, Glassman AR, Googe JM, Jampol LM, Martin DF, Melia M, Preston CM, Wykoff CC, Sun JK; DRCR Retina Network. Association of Ultra-Widefield Fluorescein Angiography–Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. Published online August 18, 2022. doi:10.1001/jamaophthalmol.2022.3130 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
5. Ehlers JP, Josic K, Yordi S, Martin A, Srivastava SK, Sun JK; DRCR Retina Network. Assessment of Baseline Ultrawidefield Fluorescein Angiographic Quantitative Leakage Parameters with Ultrawidefield Fundus Features and Clinical Parameters in Diabetic Retinopathy in Protocol AA. Ophthalmol Retina. 2024 Aug 30:S2468-6530(24)00402-0. doi: 10.1016/j.oret.2024.08.015. Epub ahead of print (Published).
(Manuscript)   
 
6. Silva PS, Liu D, Aiello LP, Melia M, Sun JK; DRCR Retina Network. Diabetic Retinopathy Lesion Types and Distribution on Ultrawide Field Imaging and the Risk of Disease Worsening Over Time. Retina. 2024 Sep 12. doi: 10.1097/IAE.0000000000004263. Epub ahead of print. (Published).
(Manuscript)   
 

Protocol AB - Vitreous Hemorrhage from PDR Study

1. Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, Salehi-had H, Wells JA 3RD, Maguire MG, Stockdale CR, Martin DF, Sun JK. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: A randomized clinical trial. JAMA. 2020; 324(23):2383-2395. doi: 10.1001/jama.2020.23027 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Glassman AR, Beaulieu WT, Maguire MG, Antoszyk AN, Chow CC, Elman MJ, Jampol LM, Salehi-Had H, Sun JK, for the DRCR Retina Network. Visual acuity, vitreous hemorrhage, and other ocular outcomes after vitrectomy vs aflibercept for vitreous hemorrhage due to diabetic retinopathy: A secondary analysis of a randomized clinical trial. JAMA Ophthalmol.2021 Jul; 139(7): 1–9. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol AC - Aflibercept vs. Bevacizumab with deferred Aflibercept for DME

1. Jhaveri CD, Glassman AR, Ferris FL, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK, DRCR Retina Network. Aflibercept monotherapy versus bevacizumab first followed by aflibercept if needed for treatment of center-involved diabetic macular edema. NEJM. Published online July 14, 2022. DOI: 10.1056/NEJMoa2204225 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Hutton DW, Glassman AR, Liu D, Sun JK, DRCR Retina Network. Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. JAMA Ophthalmol. Published online February 02, 2023. doi:10.1001/jamaophthalmol.2022.6142 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
3. Chirag D. Jhaveri, Danni Liu, Maureen G. Maguire, Adam R. Glassman, Ruben A. Grigorian, Lee M. Jampol, Ronald M. Kingsley, Mathew W. MacCumber, Daniel F. Martin, Raj K. Maturi, Gisela Velez, Jennifer K. Sun, DRCR Retina Network. Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity <20/40. Ophthalmology, 2024,ISSN 0161-6420, https://doi.org/10.1016/j.ophtha.2024.01.037. (In-Press).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol AE - Photobiomodulation for DME Study

1. Kim JE, Glassman AR, Josic K, Melia M, Aiello LP, Baker C, Eells JT, Jampol LM, Kern TS, Marcus D, Martin DF, Salehi-Had H, Shah SN, Stockdale CR, Sun JK for the DRCR Retina Network. A randomized trial of photobiomodulation therapy for center-involved diabetic macular edema with good visual acuity (Protocol AE). Ophthalmol Retina. 2022 Apr;6(4):298-307. doi: 10.1016/j.oret.2021.10.003. Epub 2021 Oct 8 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol AG - PVL with Gas for VMT Randomized Trial

1. Chan CK, Mein CE, Glassman AR, Beaulieu WT, Calhoun CT, Jaffe GJ, Jampol LM, MacCumber MW, Maguire MG, Maturi RK, Salehi-Had H, Rofagha S, Sun JK, Martin DF, DRCR Retina Network. Pneumatic Vitreolysis with C 3 F 8 for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. Ophthalmology. 2021 May 11;S0161-6420(21)00353-5. doi: 10.1016/j.ophtha.2021.05.005 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol AK - Home OCT Monitoring System: Feasibility Study

1. Blinder KJ, Calhoun C, Maguire MG, Glassman AR, Mein CE, Baskin DE, Vieyra G, Jampol LM, Chica MA, Sun JK, Martin DF; DRCR Retina Network. Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study. Ophthalmol Retina. 2024 Apr;8(4):376-387. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol B - Intravitreal Triamcinolone Acetonide versus Laser Study

1. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol.2007 Sep;144(3):454-6 (Published).
(Manuscript) |  View Publication   
 
2. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina.2008 Jul-Aug;28(7):919-30 (Published).
(Manuscript) |  View Publication   
 
3. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology.2008 Sep;115(9):1447-9.e1-10 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
4. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol.2009 Mar;127(3):245-51 (Published).
(Manuscript) |  View Publication   
 
5. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009 Dec;127(12):1566-71 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
6. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris FL, Glassman AR, Ip MS, Miller KM, for the Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010 May;117(5):946-953 (Published).
(Manuscript) |  View Publication   
 
7. Lauer AK, Bressler NM, Edwards AR, for the Diabetic Retinopathy Clinical Research Network. Frequency of Intraocular Pressure Increase within Days After Intravitreal Triamcinolone Injections in the Diabetic Retinopathy Clinical Research Network. Arch Ophthalmol. 2011 Aug;129(8):1097-1099. (Published).
(Manuscript) |  View Publication   
 

Protocol C - OCT Diurnal Variation Study

1. Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3rd. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol.2006 Dec;124(12):1701-7 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network, Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology.2007 Aug;114(8):1520-5 (Published).
(Manuscript) |  View Publication   
 

Protocol D - Vitrectomy Study

1. Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net, Haller JA, Qin H, Apte RS, Beck RW, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010 Jun;117:1087-1093.e3 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Diabetic Retinopathy Clinical Research Network. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema. Retina. 2010 Oct;30(9):1488-95 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol E - Peribulbar Triamcinolone Acetonide Study

1. Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, Beck R, Aiello LP, Antoszyk A, Bressler N, Browning D, Danis R, Fan J, Flaxel C, Friedman S, Glassman A, Kollman C, Lazarus H.. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology.2007 Jun;114(6):1190-6 (Published).
(Manuscript) |  View Publication   
 
2. Chew EY, Glassman AR, Beck RW, Bressler NM, Fish GE, Ferris FL, Kinyoun JL; Diabetic Retinopathy Clinical Research Network. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina. 2011 Feb;31(2):284-9 (Published).
(Manuscript) |  View Publication   
 

Protocol F - PRP Study

1. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol.2009 Feb;127(2):132-40 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol G - Subclinical Diabetic Macular Edema Study

1. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol.2008 May;145(5):894-901 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network. Observational Study of Subclinical Diabetic Macular Edema. Eye (Lond). 2012 Jun;26(6):900-1 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol H - Bevacizumab (Avastin) Phase 2 Study

1. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology.2007 Oct;114(10):1860-7 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina.2008 Jan;28(1):36-40 (Published).
(Manuscript) |  View Publication   
 

Protocol I - Laser-Ranibizumab-Triamcinolone for DME

1. Diabetic Retinopathy Clinical Research Network. Expanded 2-year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2011 Apr;118(4):609-14. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. The Diabetic Retinopathy Clinical Research Network. Rationale for the Diabetic Retinopathy Clinical Research Network Intravitreal Anti-VEGF Treatment and Follow-up Protocol for Center-involved Diabetic Macular Edema. Ophthalmology. 2011 Dec;118:e5-e14 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
3. Glassman AR, Stockdale CR, Beck RW, Baker C, Bressler NM; for the Diabetic Retinopathy Clinical Research Network. Evaluation of Masking Study Participants to Intravitreal Injections in a Randomized Clinical Trial. Arch Ophthalmol. 2012 Feb;130(2):190-194 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
4. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 June;117(6):1064-1077.e35 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
5. Bressler S, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA, for the Diabetic Retinopathy Clinical Research Network. Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema with Ranibizumab. Arch Ophthalmol. 2012 Sep;130(9):1153-1161 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
6. The Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL III, Glassman AR, Maturi RK, Melia M. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year Randomized Trial Results. Ophthalmology 2012;119:2312–18 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
7. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Stone T, for the Diabetic Retinopathy Clinical Research Network. Exploratory Analysis of Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial. JAMA Ophthalmol. 2013; 131(8):1033-1040 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
8. Bressler SB, Almukhtar T, Aiello LP, Bressler NM, Ferris FL III, Glassman AR, Greven CM, for the Diabetic Retinopathy Clinical Research Network. Green or Yellow Laser Treatment for Diabetic Macular Edema: Exploratory Assessment within the Diabetic Retinopathy Clinical Research Network. Retina. 2013 Nov-Dec;33(10):2080-8. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
9. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW; Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology. 2015 Feb;122(2):375-81. doi: 10.1016/j.ophtha.2014.08.047. Epub 2014 Oct 28. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
10. Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang S, Jampol LM, Kim JE, Melia M, for the Diabetic Retinopathy Clinical Research Network. Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained IOP Elevation or Ocular Hypotensive Treatment. JAMA Ophthalmol. JAMA Ophthalmol. 2015 May 1;133(5):589-97. doi:10.1001/jamaophthalmol.2015.186 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
11. Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, for the Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy prior to anti-vascular endothelial growth factor therapy. Retina. 2015 Dec;35(12):2516-28. doi: 10.1097/IAE.0000000000000617 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
12. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME, for the Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016 Mar 1;134(3):278-85. doi: 10.1001/jamaophthalmol.2015.5346 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
13. Diabetic Retinopathy Clinical Research Network. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol. 2016 Apr;164:57-68. doi: 10.1016/j.ajo.2015.12.025. Epub 2016 Jan 21. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
14. Bressler SB, Odia I, Glassman AR, Danis RP, Grover S, Hampton GR, Jampol LM, Maguire M, Melia M, for the Diabetic Retinopathy Clinical Research Network. Changes in Diabetic Retinopathy Severity When Treating Diabetic Macular Edema with Ranibizumab: DRCR.net Protocl I 5-Year Report. Retina.Oct 2018;38(10):1896-1904 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol J - Laser-Ranibizumab-Triamcinolone for DME Plus PRP

1. Diabetic Retinopathy Clinical Research Network. Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema Following Focal/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina. 2011 June;31(6):1009-27 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol K - Laser Response

1. Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. Retina.2009 Nov-Dec;29(10):1436-43 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol L - Autorefraction and VA Reproducibility Study

1. The Diabetic Retinopathy Clinical Research Network. Evaluation of Visual Acuity Measurements after Autorefraction versus Manual Refraction in Eyes with and without Diabetic Macular Edema. Arch Ophthalmol. 2012 Apr; 130:470-479 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol M - Diabetes Education Study

1. Diabetic Retinopathy Clinical Research Network. Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2015 Aug;133(8):888-96. doi: 10.1001/jamaophthalmol.2015.1312. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol N - Intravitreal Ranibizumab for Vitreous Hemorrhage from PDR Study

1. Diabetic Retinopathy Clinical Research Network. Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2013 Mar 1;131(3):283-93. doi: 10.1001/jamaophthalmol.2013.2015. (Published).
(Manuscript) |  View Publication   
 
2. Bhavsar AR, Torres K, Bressler NM, Glassman AR, Jampol LM, Kinyoun JL, for the Diabetic Retinopathy Clinical Research Network. Evaluation of Results 1 Year Following Use of Short-Term Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. JAMA Ophthalmol. July 2014;132(7):889-890 (Published).
(Manuscript) |  View Publication   
 

Protocol O - TD/SD OCT Comparison and Reproducibility

1. Diabetic Retinopathy Clinical Research Network. Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence Tomography. IOVS December 2012 53:8154-8161 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network Writing Committee. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol. 2014 Sep;132(9):1113-22. doi: 10.1001/jamaophthalmol.2014.1698 (Published).
(Manuscript) |  View Publication   
 
3. Susan B. Bressler, Allison R. Edwards, Christopher M. Andreoli, Paul Andrew Edwards, Adam R. Glassman, Glenn J. Jaffe, Michele Melia, Jennifer K. Sun, and for the Diabetic Retinopathy Clinical Research Network/Writing Committee. Reproducibility of Optovue RTVue Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Zeiss Stratus Metrics in Diabetic Macular Edema. Trans. Vis. Sci. Tech.: January/February 2015, Vol. 4, No. 1. doi: http://dx.doi.org/10.1167/tvst.4.1.5 (Published).
(Manuscript) |  View Publication   
 
4. Sun JK, Josic K, Melia M, Glassman AR, Bailey C, Chalam KV, Chew EY, Cukras C, Grover S, Jaffe GJ, Lee R, Nielsen JS, Thompson DJS, Wiley HE, Ferris FL 3rd; DRCR Retina Network.. Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments. Transl Vis Sci Technol. 2021 Dec 1;10(14):34. doi: 10.1167/tvst.10.14.34. (Published).
(Manuscript) |  View Publication   
 

Protocol P - Cataract Surgery with Center-Involved DME Study

1. Diabetic Retinopathy Clinical Research Network. Pilot Study of Individuals with Diabetic Macular Edema Undergoing Cataract Surgery. JAMA Ophthalmol. 2014 Feb 1;132(2):224-6. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol Q - Cataract Surgery without Center-Involved DME Study

1. Diabetic Retinopathy Clinical Research Network. Writing Committee: Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S, Kim SJ, Murtha TJ, Rauser ME, Stockdale C.. Macular Edema After Cataract Surgery In Eyes Without Pre-operative Central-involved Diabetic Macular Edema. JAMA Ophthalmol. 2013 Jul;131(7):870-9. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol R - Phase II non-Central DME NSAID Study

1. Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M, Diabetic Retinopathy Clinical Research Network. Topical Nepafenec in Eyes with Non-Central Diabetic Macular Edema. Retina. 2015 May;35(5):944-56. doi: 10.1097/IAE.0000000000000403 (Published).
(Manuscript) |  View Publication   
 

Protocol S - Prompt PRP vs Ranibizumab+Deferred PRP for PDR Study

1. Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Trial. JAMA. 2015; 314(20):2137-2146. doi: 10.1001/jama.2015.15217 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Gross JG, Glassman AR. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmol. 2016 Jan;134(1):13-4.DOI: 10.1001/jamaophthalmol.2015.5079 (Published).
(Manuscript)   
 
3. Gross JG, Glassman AR. Comment and Response, Panretinal Photocoagulation vs Anti-Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy: Author Reply. JAMA Ophthalmol.2016 June;134(6):715-16 (Published).
(Manuscript)   
 
4. Beaulieu WT, Bressler NM, Melia M, Owsley C, Mein CE, Gross JG, Jampol LM, Glassman AR, for the Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes from a Randomized Clinical Trial. Am J Ophthalmol. 2016 Oct;170:206-213. doi: 10.1016/j.ajo.2016.08.008. Epub 2016 Aug 12. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
5. Beaulieu WT, Bressler NM, Gross JG. Author Reply.Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Amer J Ophthal. 2017;177:223. DOI: http://dx.doi.org/10.1016/j.ajo.2017.02.010 (Published).
(Manuscript)   
 
6. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Melia M, Peters MA, Rauser ME, for the Diabetic Retinopathy Clinical Research Network. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology. 2017 Apr;124(4):431-439. doi: 10.1016/j.ophtha.2016.12.005. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
7. Hutton DW, Stein JD, Bressler NM,Jampol LM, Browning D, Glassman AR, for the Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for PDR: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. JAMA Ophthalmol. 2017 Jun 1;135(6):576-584. doi: 10.1001/jamaophthalmol.2017.0837. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
8. Gross JG, Glassman AR, Klein MJ, Ferris FL, Bressler NM, Beck RW. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2017 Jun 1;135(6):672-673. doi: 10.1001/jamaophthalmol.2017.0969 (Published).
(Manuscript) |  View Publication   
 
9. Bressler SB, Beaulieu WT, Glassman AR. Reply:Re: Bressler et al.: Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab (Ophthalmology. 2017;124:431-439). December 2017;124(12):e88–e89 (Published).
(Manuscript)   
 
10. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Melia M, Chen Eric, Pavlica MR, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Factors accociated with vision and edema outcomes. Ophthalmology. 2018 Nov;125(11):1776-1783. doi: 10.1016/j.ophtha.2018.04.039 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
11. Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL, Gardner TW, Jampol LM, Martic DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
12. Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, Gross JG, Shami M, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Rationale and Application of the Protocol S Anti–Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2019 Jan; 126 (1): 87-95 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
13. Jampol LM, Odia I, Glassman AR, Baker CW, Bhorade AM, Han DP, Jaffe GJ, Melia M, Bressler NM, Tanna AP. Panretinal Photocoagulation vs Ranibizumab for Proliferative Diabetic Retinopathy: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. RETINA. 2019 Jan; 39(1):69-78 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
14. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Melia BM, Chen E, Pavlica MR, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Photocoagulation versus Ranibizumab for Proliferative Diabetic Retinopathy: Should Baseline Characteristics Affect Choice of Treatment?. Retina. 2019 Sep;39(9):1646-1654 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
15. Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Sun JK9; DRCR Retina Network. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2019 Dec 1;137(12):1424-1432. doi: 10.1001/jamaophthalmol.2019.4284 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
16. Glassman AR, Beaulieu WT, Stockdale CR, Beck RW, Bressler NM, Labriola LT, Melia M, Oliver K, Sun JK, for the DRCR Retina Network. Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trial. Clin Trials. 2020 Apr;17(2):195-201. doi: 10.1177/1740774519894229. Epub 2020 Jan 27 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
17. Maguire MG, Liu D, Glassman AR, Jampol LM, Johnson CA, Baker CW, Bressler NM, Gardner TW, Pieramici D, Stockdale CR, Sun JK; DRCR Retina Network.. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2020 Jan 30. doi: 10.1001/jamaophthalmol.2019.5939. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
18. Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, Glassman AR, Sun JK; DRCR Retina Network. Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021 Dec 1;139(12):1266-1273. doi: 10.1001/jamaophthalmol.2021.4103. PMID: 34673898; PMCID: PMC8532036 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
19. Lee B, Josic K, Nittala MG, Velaga SB, Karamat A, Srinivas S, Corvi F, Singh G, Sadda S, Sun JK, Ip M, for the DRCR Retina Network. Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity. Transl Vis Sci Technol. 2024 Jul 1;13(7):19. doi: 10.1167/tvst.13.7.19. (Published).
(Manuscript) |  View Publication   
 

Protocol T - Aflibercept, Bevacizumab and Ranibizumab Comparison for DME Study

1. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Mar 26; 372(13): 1193–1203. DOI: 10.1056/NEJMoa1414264 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Wells JA, Glassman AR, Jampol LM. Targeting the Effect of VEGF in Diabetic Macular Edema: Author Reply. N Engl J Med 2015; 373:479-482.July 30, 2015.DOI: 10.1056/NEJMc1505684 (Published).
(Manuscript) |  View Publication   
 
3. Jampol LM, Glassman AR, Bressler NM. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2015 Sep;133(9):983-4. doi: 10.1001/jamaophthalmol.2015.1880 (Published).
(Manuscript) |  View Publication   
 
4. Jampol LM, Glassman AR, Bressler NM, Wells JA, Ayala AR, for the Diabetic Retinopathy Clinical Research Network. Anti–Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol. 2016;134(12):1429-1434. doi:10.1001/jamaophthalmol.2016.3698 (Published).
(Manuscript) |  View Publication   
 
5. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016;134(8):888-896. doi:10.1001/jamaophthalmol.2016.1669. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
6. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 2016;123(6):1351-9. doi.org/10.1016/j.ophtha.2016.02.022 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
7. Wells JA, Glassman AR, Ayala AR, Jampol LM. Author Reply. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2017 Jan;124(1):e5-e6. doi: 10.1016/j.ophtha.2016.04.032. (Published).
(Manuscript)   
 
8. Bressler NM, Glassman AR, Hutton DW. Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply. JAMA Ophthalmol. 2017 Mar 1;135(3):291-292 (Published).
(Manuscript) |  View Publication   
 
9. John A. Wells, Adam R. Glassman, Lee M. Jampol, Lloyd Paul Aiello, Andrew N. Antoszyk, Carl W. Baker, Neil M. Bressler, David J. Browning, Crystal G. Connor, Michael J. Elman, Frederick L. Ferris, Scott M. Friedman, Michele Melia, Dante J. Pieramici, Jennifer K. Sun, Roy W. Beck, for the Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness with 1-year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
10. John A. Wells, Adam R. Glassman, Lee M. Jampol, Allison Ayala, Neil M. Bressler. Author Reply. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2017 Mar;124(3):e26-e27. http://dx.doi.org/10.1016/j.ophtha.2016.07.001 (Published).
(Manuscript)   
 
11. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017 Jun 1;135(6):558-568. doi: 10.1001/jamaophthalmol.2017.0821 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
12. Wells JA, Glassman AR, Bressler NM, Ayala AR, Jampol LM. Author Reply. Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2017 Apr;124(4):e38-e39. doi: 10.1016/j.ophtha.2016.08.032. (Published).
(Manuscript)   
 
13. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved DME With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
14. Glassman AR, Liu D, Jampol LM, Sun JK, for the Diabetic Retinopathy Clinical Research Network. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1199-1205. doi: 10.1167/iovs.17-22853. (Published).
(Manuscript) |  View Publication   
 
15. Jampol LM, Glassman AR, Liu D, Aiello L Paul, Bressler NM, Duh EJ,Quaggin S, Wells JA, Wykoff CC, for the Diabetic Retinopathy Clinical Research Network. Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for Diabetic Macular Edema. Ophthalmology. 2018 Jul;125(7):1054-1063. doi: 10.1016/j.ophtha.2018.01.019. Epub 2018 Mar 7. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
16. Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, Gonzalez VH, Jampol LM, Melia M, Sun JK, Wells JA, for the Diabetic Retinopathy Clinical Research Network. Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. Am J Ophthalmol. 2018 Nov;195:93-100. doi: 10.1016/j.ajo.2018.07.030. Epub 2018 Aug 2 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
17. Glassman AR, Duh EJ, Liu D, Jampol LM. Author Reply. Re. Du et al.: Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 Nov;125(11):e82. doi: 10.1016/j.ophtha.2018.05.004. (Published).
(Manuscript)   
 
18. Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK; Diabetic Retinopathy Clinical Research Network. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. 2019 Apr 1;137(4):382-389 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
19. Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK; DRCR Retina Network. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol.2019 Jun 27.doi:10.1001/jamaophthalmol.2019.1963. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol TX - Aflibercept, Bevacizumab and Ranibizumab Comparison for DME – Follow-up Extension Study

1. Glassman AR, Wells JA 3RD, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK, for the Diabetic Retinopathy Clinical Research Network. Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmol. 2020 Aug; 127 (9): 1201-10 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol U - Phase II Combination Steroid and Anti-VEGF for Persistent DME Study

1. Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan 1;136(1):29-38. doi: 10.1001/jamaophthalmol.2017.4914. (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol V - Treatment for CI-DME with Very Good VA Study

1. Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019 May 21;321(19):1880-1894 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Adam R Glassman, Carl W Baker, Wesley T Beaulieu, Neil M Bressler, Omar S Punjabi, Cynthia R Stockdale, Charles C Wykoff, Lee M Jampol, Jennifer K Sun, DRCR Retina Network. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 Feb 20;138(4):341-349. doi: 10.1001/jamaophthalmol.2019.6035 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
3. Beaulieu WT, Glassman AR, Baker CW, Maguire MG, Johnson CA, Melia M, Sun JK, for the DRCR Retina Network. Effect of initial aflibercept, laser, or observation on low-contrast visual acuity in eyes with diabetic macular edema and good vision: Ancillary study within a randomized clinical trial. Trans Vis Sci Tech. 2021;10(3):3,ttps://doi.org/10.1167/tvst.10.3.3 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
4. Hutton DW, Glassman AR, Stein JD, Bressler NM, Sun JK, for the DRCRT Retina Network. Costs of managing diabetic macular edema with good visual acuity with aflibercept, laser, or observation: DRCR Retina Network Protocol V. Am J Ophthalmol.2021 Oct;230:297-302.DOI:https://doi.org/10.1016/j.ajo.2021.02.033 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 

Protocol W - Anti-VEGF for PDR/DME Prevention Study

1. Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, Marcus DM, Martin DF, Melia M, Salehi-Had H, Stockdale CR, Punjabi OS, Sun JK, DRCR Retina Network. Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. JAMA Ophthalmol. 2021 Jul 1;139(7):701-712. doi: 10.1001/jamaophthalmol.2021.0606 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
2. Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA. 2023;329(5):376–385. doi:10.1001/jama.2022.25029 (Published).
(Manuscript) |  View Publication  |  View Presentation  
 
3. Sun JK, Glassman AR, Maturi RK; DRCR Retina Network. Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-Reply. JAMA. 2023 May 23;329(20):1796. doi: 10.1001/jama.2023.6715. PMID: 37219555 (Published).
(Manuscript)